Medical devices, healthcare technology and the business of care
510(k) clearance · K261712

Ceribell EEG Analysis Software

Ceribell, Inc. · Decision date Sep 16, 2026

MEDTECHLEDGER EXPLANATIONK261712

What did the FDA decide?

Ceribell, Inc. received a substantially equivalent (SESE) decision for its Ceribell EEG Analysis Software under 510(k) K261712, dated September 16, 2026, with the FDA public record listing a receipt date of May 22, 2026. The device is a Class II electroencephalograph under 21 CFR 882.1400, product codes OLT and OMA, in the neurology specialty. SESE is a clearance to market, not premarket approval.

The software is intended for review, monitoring and analysis of EEG recordings from scalp-electrode EEG devices, with quantitative measures including frequency band metrics and burst suppression, plus aEEG functionality; the summary states these measures should be interpreted with the original waveforms. The summary names encevis (K240993) as primary predicate and states the subject device claims a subset of functions, excluding automatic seizure or spike detection. The letter and summary give conflicting receipt dates, and the summary's predicate product codes differ from the public record; performance data are not described here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Sep 16, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261712
Regulatory pathway
510(k) premarket notification
Product code
OLT
Decision code
SESE
Decision date
Sep 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Non-Normalizing Quantitative Electroencephalograph Software.

Product code
OLT
FDA device class
2

FDA decision timeline

  1. K261712 received

    Application receipt date recorded by FDA.

  2. K261712 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ceribell, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Sunnyvale, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records